Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!
Learn MoreA wide range of antibody discovery technologies and techniques have emerged in the past decade, driving a new era of potent antibody therapeutics and therapeutic strategies, including multi-specific antibodies and antibody-drug conjugates. Alfa Cytology has implemented a diverse toolbox of antibody discovery technology platforms to generate highly specific high-affinity antibodies for bladder cancer.
The process of antibody discovery involves the utilization of structural computation and library generation to screen the properties of antibodies and antibody-like molecules for subsequent research approaches. The initial phase of discovery primarily focuses on identifying antibody binding properties or "hits" before progressing to pre-clinical. Throughout this discovery phase, antibody researchers customize affinity and stability to achieve improved outcomes for potential therapeutic candidates.
Fig.1 Types of antibody phage display libraries, library construction, and antibody selection. (Zhang Y., 2023)
With Alfa Cytology's extensive expertise in antibody discovery, we offer dedicated services for both end-to-end antibody discovery and standalone antibody discovery. Our goal is to be your sole partner for all your antibody discovery needs and beyond.
Immunization Strategies
Antibody Library Construction
Antibody Screening and Selection
Collaborate with Alfa Cytology throughout the entire antibody discovery process or selectively utilize their services to effectively develop and evaluate your bladder cancer-specific antibody. To learn more about our services or to discuss your specific research needs, please contact us.
Reference
Alfa Cytology is dedicated to drug development and preclinical services for bladder cancer.